Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
← catalyst calendarNCT06899204 · readout in 179 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
150estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-24 | actual | When the study began enrolling |
| Primary completion | 2027-02-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis
- Atopic Dermatitis, Unspecified
- Dermatitis, Atopic
Intervention
- Drug: Abrocitinib — also filed as Cibinqo
Primary outcomes
what the primary-completion date above is the date OFPercentage of patients achieving EASI-75 improvement from baseline at Week 16 after index date
measured Baseline, week 16
Percentage of patients achieving ≥ 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS) collected daily all through the study from baseline at Week 2 by e-diary assessment
measured Baseline, week 2
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed